Thoratec Makes Case For Permanent VAD Higher Medicare Reimbursement
This article was originally published in The Gray Sheet
Executive Summary
Thoratec is expecting CMS to boost Medicare reimbursement for mechanical cardiac assist device implantation based on data showing that the firm's HeartMate XVE left ventricular assist device (LVAD) is a cost-effective destination therapy for end-stage heart failure patients
You may also be interested in...
Vulnerable Plaque Natural History Key To Device Trial, Swift Approvals
Clinical trials supporting devices and diagnostics for vulnerable plaques (VP) should include analysis of the natural history of the vascular disease, according to FDA Office of Device Evaluation's Donald Jensen
Vulnerable Plaque Natural History Key To Device Trial, Swift Approvals
Clinical trials supporting devices and diagnostics for vulnerable plaques (VP) should include analysis of the natural history of the vascular disease, according to FDA Office of Device Evaluation's Donald Jensen
IPPS Final Rule Creates New DRG 525, Increases Reimbursement For LVADs
Thoratec plans to work with the Centers for Medicare & Medicaid Services to further improve reimbursement levels for implantation of left ventricular assist devices as destination therapy